BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12895502)

  • 1. Neocortical neurons cultured from mice with expanded CAG repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults.
    Snider BJ; Moss JL; Revilla FJ; Lee CS; Wheeler VC; Macdonald ME; Choi DW
    Neuroscience; 2003; 120(3):617-25. PubMed ID: 12895502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.
    Conforti P; Camnasio S; Mutti C; Valenza M; Thompson M; Fossale E; Zeitlin S; MacDonald ME; Zuccato C; Cattaneo E
    Neurobiol Dis; 2013 Feb; 50():160-70. PubMed ID: 23089356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
    Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
    Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
    J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HD CAG-correlated gene expression changes support a simple dominant gain of function.
    Jacobsen JC; Gregory GC; Woda JM; Thompson MN; Coser KR; Murthy V; Kohane IS; Gusella JF; Seong IS; MacDonald ME; Shioda T; Lee JM
    Hum Mol Genet; 2011 Jul; 20(14):2846-60. PubMed ID: 21536587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
    Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
    J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
    Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
    Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.
    Reis SA; Thompson MN; Lee JM; Fossale E; Kim HH; Liao JK; Moskowitz MA; Shaw SY; Dong L; Haggarty SJ; MacDonald ME; Seong IS
    Hum Mol Genet; 2011 Jun; 20(12):2344-55. PubMed ID: 21447599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
    Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
    J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
    Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
    J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease.
    Fernandes HB; Baimbridge KG; Church J; Hayden MR; Raymond LA
    J Neurosci; 2007 Dec; 27(50):13614-23. PubMed ID: 18077673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
    Jana NR; Zemskov EA; Wang Gh ; Nukina N
    Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
    Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
    Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
    Choudhury KR; Das S; Bhattacharyya NP
    J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
    Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
    FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
    Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
    J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
    Hansson O; Petersén A; Leist M; Nicotera P; Castilho RF; Brundin P
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8727-32. PubMed ID: 10411943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.